Although accumulating evidence has linked well‒established clinicopathological factors—younger age, higher clinical, pathologic stage, tumor grade, or Ki-67 expression—to BM risk [15,26], the specific molecular mechanisms underlying BM development based on treatment response remain unclear. This evidence concerns the gene MKI67 and neoplasm.